Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | PDE9A | O76083 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24866878 | 0.87 | PDE9A (0.38) | PDE9A | |
| SCHEMBL21388735 | 0.82 | KDM5A (0.37) | HSD17B10ALDH1A1 | |
| SCHEMBL24866843 | 0.81 | KDM5A (0.39) | HSD17B10ALDH1A1 | |
| SCHEMBL21399364 | 0.77 | CNR2 (0.32) | HSD17B10ALDH1A1HPGDCYP3A4CYP2D6 | |
| SCHEMBL24866713 | 0.76 | PTPN11 (0.41) | — | |
| SCHEMBL21399141 | 0.75 | — | — | |
| SCHEMBL23173104 | 0.75 | PTPN11 (0.44) | — | |
| SCHEMBL21399329 | 0.75 | ENPP1 (0.32) | PDE9A | |
| SCHEMBL21399254 | 0.75 | PDE9A (0.36) | PDE9A | |
| SCHEMBL24866507 | 0.74 | ENPP1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2023-01-12 | — | — | US | disclosed |
| US-10561655-B2 | SHP2 inhibitors and uses thereof | SYNBLIA THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190290649-A1 | SHP2 INHIBITORS AND USES THEREOF | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | PTPN1, PTPN7, PTPN18 | HSD17B10 2308/4885ALDH1A1 3180/4885HPGD 2665/4885 |
| US-20190290649-A1 | SHP2 INHIBITORS AND USES THEREOF | PTPN1, PTPN7, PTPN18 | HSD17B10 2308/4885ALDH1A1 3180/4885HPGD 2665/4885 |
| US-10561655-B2 | SHP2 inhibitors and uses thereof | PTPN1, PTPN7, PTPN18 | HSD17B10 2308/4885ALDH1A1 3180/4885HPGD 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.